Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Camrelizumab as second-line therapy for advanced biliary tract cancer
ChiCTR2300073743Phase 4Not yet recruiting
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib and camrelizumab in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by General Hospital of Eastern Military Command. Primary endpoint: Progression-free survival. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
surufatinibcamrelizumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2300073743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073743.